Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Management of Chronic Kidney Disease Stages 1–3

Slide: 16 of 29

Clinical Bottom Line: Risk for Mortality in Patients With CKD Stages 1–3 Treated With ACEIs or ARBs (1 of 2)

The risk for mortality was not significantly different in patients with CKD stages 1–3 who were treated with a placebo versus an ACEI, an ARB, or an ACEI plus a diuretic. The risk for mortality was also not significantly different in patients with CKD stages 1–3 who were treated with an ACEI versus an ARB, a CCB, or a beta-blocker; an ARB versus a CCB; an ACEI plus an ARB versus an ACEI alone; or an ACEI plus an ARB versus an ACEI or ARB alone.

Abbreviations:
ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; CCB = calcium channel blocker; CKD = chronic kidney disease; SOE = strength of evidence